<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03017183</url>
  </required_header>
  <id_info>
    <org_study_id>WI_EBUS-TBNA_16-226</org_study_id>
    <nct_id>NCT03017183</nct_id>
  </id_info>
  <brief_title>Detection of Heterogeneity in Central Lung Cancer - EBUS-TBNA and ctDNA Analysis vs. Endobronchial Forceps Biopsy</brief_title>
  <official_title>Detection of Heterogeneity in Central Lung Cancer - Prospective Randomized Controlled Trial to Evaluate the Diagnostic Value of EBUS-TBNA and ctDNA Analysis Compared to Endobronchial Forceps Biopsy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wissenschaftliches Institut Bethanien e.V</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institute of Pathology, University Clinic DÃ¼sseldorf</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Wissenschaftliches Institut Bethanien e.V</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study participants will be selected from clinical routine patients with endobronchial
      infiltration of a central lung cancer and indication for bronchoscopic sampling.

      Consented patients will undergo bronchoscopy for tumor sampling applying two routine sampling
      methods during one single procedure (EBUS-TBNA and conventional forceps sampling). The
      sequence of both sampling methods will be randomized in advance.

      The resulting tissue samples will be analyzed by a pathologist using multiplex PCR and FISH.
      The corresponding analysis results will be compared between sampling methods.

      Assignment of a subject to a particular therapeutic strategy is not influenced by this
      protocol. Medicinal products will be used according to current practice and marketing
      authorisation.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2016</start_date>
  <completion_date type="Anticipated">November 2018</completion_date>
  <primary_completion_date type="Anticipated">November 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of detected mutations</measure>
    <time_frame>within 7 days after biopsy</time_frame>
    <description>The number of different mutations detected based on each biopsy method as well as ctDNA analysis is determined</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Lung Neoplasms</condition>
  <arm_group>
    <arm_group_label>EBUS-TBNA - Endobrochial Forceps Biopsy</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>In this arm, EBUS-TBNA will be done first, followed by endobronchial forceps biopsy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Forceps - EBUS-TBNA</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>In this arm, endobronchial forceps biopsy will be done first, followed by EBUS-TBNA</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>EBUS-TBNA</intervention_name>
    <description>Endobronchial ultrasound guided transbronchial needle aspiration</description>
    <arm_group_label>EBUS-TBNA - Endobrochial Forceps Biopsy</arm_group_label>
    <arm_group_label>Forceps - EBUS-TBNA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Endobronchial forceps biopsy</intervention_name>
    <description>Conventional endobronchial forceps biopsy</description>
    <arm_group_label>EBUS-TBNA - Endobrochial Forceps Biopsy</arm_group_label>
    <arm_group_label>Forceps - EBUS-TBNA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

        Subjects eligible for enrolment in the study must meet all of the following criteria:

          1. Informed consent: a signed and dated written informed consent prior to study
             participation.

          2. Type of subject: inpatient

          3. Age: subjects of more than 18 years and less than 85 years.

          4. Central lesion in computed tomography highly suspicious of lung cancer with clinical
             indication for further diagnostic applying bronchoscopy.

          5. Central lesion has to be accessible by the biopsy techniques under investigation

        Exclusion criteria:

        Subjects meeting any of the following criteria must not be enrolled in the study:

          1. Females who are pregnant or lactating , who decide not to undergo a bronchoscopy due
             to the risk for their child

          2. Any contraindication for bronchoscopy and EBUS-TBNA (IBNLT: INR&gt;2, thrombocytopenia
             &lt;40/nl)

          3. Drug/alcohol abuse impairing cognitive knowledge which is needed for a GCP conform
             informed consent.

          4. Inability to read or inability of language: in the opinion of the investigator, any
             subject who is unable to read and/or would not be able to complete study related
             materials.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>84 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Winfried J Randerath, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wissenschaftliches Institut Bethanien e.V</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marcel Treml, Dr.</last_name>
    <phone>+49212636661</phone>
    <email>marcel.treml@klinik-bethanien.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Krankenhaus Bethanien gGmbH</name>
      <address>
        <city>Solingen</city>
        <state>NRW</state>
        <zip>42699</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marcel Treml, Dr. rer. nat.</last_name>
      <phone>+49-212-636661</phone>
    </contact>
    <investigator>
      <last_name>Winfried J Randerath, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lars Hagmeyer, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 5, 2017</study_first_submitted>
  <study_first_submitted_qc>January 10, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 11, 2017</study_first_posted>
  <last_update_submitted>January 10, 2017</last_update_submitted>
  <last_update_submitted_qc>January 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

